Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study

Zhou, Ke; Blanc-Lapierre, Audrey; Seegers, Valérie; Boisdron‐Celle, Michèle; Bigot, Frédéric; Bourdon, Marianne; Mahammedi, Hakim; Lambert, Aurélien; Campone, Mario; Conroy, Thierry; Penault‐Llorca, Frédérique; Bellanger, Martine; Raoul, Jean‐Luc

doi:10.3390/cancers13143389

Cited by 8 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, 20 studies provided data on overall Covid-19 infectivity (99601 gynecologic cancer, 8311468 overall control population). 15,17,23,29,31,33-35,39,43,44,46,49,51,54,55,58,60 Covid-19 infection was comparable between gynecologic cancer and control (OR 0.97, CI 0.81-1.15, p 0.69, I 2 47%) Fig. S6 .…”

Section: Resultsmentioning

confidence: 95%

“…S18. 15,17,23,29,33,39,43,50,51,56,61 Data from 30 studies revealed that gynecologic cancer had fewer Covid-19 death than lung cancer patients (OR 0.52, CI 0.44-.062, p <0.0001, I 2 0%) Figure 6A. 15,[18][19][20][21][24][25][26][27][28]30,32,37,39,[40][41][42]45,46,[48][49][50][52][53][54]57,58 Data from 6 studies showed that gynecologic cancer was having less severity from Covid-19 than lung cancer (OR 0.36, CI 0.16-0.80, p 0.01, I 2 0%) Figure 6B.…”

Section: Gynecologic Cancer Vs Lung Cancermentioning

confidence: 99%

“…S19. 15,17,29,33,39,43,46,49,50,55,60 Interestingly from 24 studies, gynecologic cancer was experiencing higher Covid-19 death compared to breast cancer patients (OR 1.51, CI 1.20-1.90, p 0.0004, I 2 21%) Figure 7A. 15,[18][19][20][25][26][27][28]30,32,37,[39][40][41][42]45,[47][48][49]52,53,56,57 Covid-19 severity was not statistically significant from 7 studies between gynecologic cancer and breast cancer (OR 0.83, CI 0.40-1.72, p 0.62, I 2 0%) Fig.…”

Section: Gynecologic Cancer Vs Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Winata

Simatupang

Polim

et al. 2022

Preprint

View full text Add to dashboard Cite

ObjectiveCancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer.MethodsSearches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557).ResultsWe accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, p 0.01), (OR 0.26, CI 0.10-0.67 p 0.005), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.51, CI 1.20-1.90, p 0.0004), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 3.06, CI 2.32-4.04, p <0.0001) respectively.ConclusionGynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.SynopsisThis is a systematic review and meta analysis study that presents pooled evidence of outcome among gynecologic cancer patients infected with the Covid-19 infection. We manage to gather 49 studies involving 1994 gynecologic cancer patients with Covid-19, 220967 non cancer patients with Covid-19, 4080990 cancer patients without Covid-19 and 28658 non gynecologic cancer patients with Covid-19 for analysis. Meta analysis shows reduction of Covid-19 death with gynecologic cancer patients vs overall other cancer, lung cancer, and hematologic cancer (OR 0.84, CI 0.72-0.97, p 0.02), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. On the contrary, increased risk of Covid-19 death occur to gynecologic cancer patients vs infected non cancer, non Covid cancer patients, and infected breast cancer patients (OR 3.06, CI 2.32-4.04, p <0.0001), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 1.51, CI 1.20-1.90, p 0.0004) respectively. Analysis from SARS-Cov-2 infection shows lower infection with gynecologic cancer patients vs hematologic cancer cohort (OR 0.71, CI 0.56-0.89, p 0.003). We hope the result of this meta analysis will be useful to providers practicing in cancer centers and tertiary cancer referral hospitals thus better practices and care services given to gynecologic cancer patients infected with / without the Covid-19 during the ongoing global pandemic can be achieved.To our knowledge this is the first systematic review and meta analysis which emphasizes on reporting the outcome of gynecologic cancer patients with the Covid-19 infection. We also found no publication bias across 49 studies we have gathered and used as meta analysis data.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Gynecologic Cancer Vs Lung Cancermentioning

confidence: 99%

Section: Gynecologic Cancer Vs Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Winata

Simatupang

Polim

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…As previously reported, from June 17, 2020 to November 30, 2020, a total of 878 CPs were included ( Table 1 ). 15 …”

Section: Resultsmentioning

confidence: 99%

“…A first analysis (from data collected in January 2021) has shown that (1) COVID (+) prevalence was 8% in CPs and 9.5% in HCWs, (2) symptom combinations were only slightly different between these two cohorts, (3) 32.1% of CPs and 51.6% of HCW had symptoms, and (4) severe outcomes were mainly observed in CPs. 15 This article aims to describe the population of asymptomatic CPs infected by SARS-COV-2 and to better understand any patterns.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)

Zhou

Raoul

Blanc-Lapierre

et al. 2022

Clin Med Insights Oncol

Self Cite

View full text Add to dashboard Cite

Background: Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors. Methods: We conducted a prospective study in CPs and health care workers (HCWs) in 4 French cancer centers (PAPESCO [ PAtients et PErsonnels de Santé des Centres de Lutte Contre le Cancer pendant l’épidémie de COvid-19] study). This analysis used data recorded between June 17, 2020 and November 30, 2020 in CPs (first 2 waves, no variants). At inclusion and quarterly, CPs reported the presence of predefined COVID-19 symptoms and had a blood rapid diagnostic test; a reverse transcription polymerase chain reaction (RT-PCR) was done in case of suspected infection. Results: A total 878 CPs were included; COVID-19 prevalence was similar in both CPs (8%) and HCWs (9.5%); of the 70 CPs (8%) who were COVID (+), 29 (41.4%) were and remained asymptomatic; 241/808 of the COVID (−) (29.8%) were symptomatic. 18 COVID (+) were hospitalized (2% of CPs), 1 in intensive care unit (ICU) and 1 died (0.1% of CPs and 2.4% of symptomatic COVID [+] CPs). Only the inclusion center was associated with clinical presentation (in Nancy, Angers, Nantes, and Clermont-Ferrand: 65.4%, 35%, 28.6%, and 10% CPs were asymptomatic, respectively). Conclusions: Seroprevalence of COVID-19 in CPs was similar to that observed in HCWs; mortality related to COVID-19 among CPs was 0.1%. More than 40% of COVID (+) CPs were asymptomatic and one third of COVID (−) CPs had symptoms. Only geographic origin was associated with the presence or absence of symptoms. Social distancing and protective measures must be applied in CPs at home and when hospitalized.

show abstract

Posttraumatic growth inventory: challenges with its validation among French cancer patients

Dubuy

Sebille

Bourdon

et al. 2022

BMC Med Res Methodol

Self Cite

View full text Add to dashboard Cite

Background The Posttraumatic growth inventory (PTGI) aims to assess the positive psychological changes that individuals can perceive after a traumatic life event such as a cancer diagnosis. Several French translations of the PTGI have been proposed, but comprehensive data on their psychometric properties are lacking. This study aimed to provide a more complete assessment of the psychometric properties of one of the most used PTGI translations in early-stage breast cancer and melanoma patients. Methods A sample of 379 patients completed the PTGI two years after their cancer diagnosis. A confirmatory analysis was first performed to determine whether the initial five-factor structure of the PTGI was adequate for this French version. As issues were identified in the translation and in the questionnaire structure, we performed an exploratory analysis to determine the most suitable structure for this questionnaire. Validity and reliability of the evidenced structured were then assessed. Results The exploratory analysis evidenced a four-factor structure close to the initial structure: four of the five initial domains were recovered, and items from the unrecovered domain were split into the other domains. This new structure showed good internal consistency and acceptable validity. Conclusions This study highlights that the process of translation and cross-cultural validation of questionnaires is crucial to obtain valid and reliable psychometric instruments. We advise French psycho-oncology researchers and psychotherapists to (i) use the revised translation of Lelorain et al. (2010) proposed in this manuscript and (ii) use the four scores newly evidenced with a grouping of two response categories.

show abstract

Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study

Cited by 8 publications

References 53 publications

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)

Posttraumatic growth inventory: challenges with its validation among French cancer patients

Contact Info

Product

Resources

About